First American Bank Takes Position in Zimmer Biomet Holdings, Inc. $ZBH

First American Bank bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,215 shares of the medical equipment provider’s stock, valued at approximately $567,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC raised its holdings in Zimmer Biomet by 0.5% in the first quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider’s stock valued at $2,903,000 after acquiring an additional 118 shares in the last quarter. Curbstone Financial Management Corp increased its holdings in shares of Zimmer Biomet by 3.4% in the 1st quarter. Curbstone Financial Management Corp now owns 4,266 shares of the medical equipment provider’s stock worth $483,000 after acquiring an additional 140 shares during the period. Brooklyn Investment Group increased its holdings in shares of Zimmer Biomet by 45.9% in the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 145 shares during the period. Roberts Wealth Advisors LLC increased its holdings in shares of Zimmer Biomet by 0.8% in the 1st quarter. Roberts Wealth Advisors LLC now owns 18,497 shares of the medical equipment provider’s stock worth $2,093,000 after acquiring an additional 152 shares during the period. Finally, Wesbanco Bank Inc. grew its position in Zimmer Biomet by 0.8% in the 1st quarter. Wesbanco Bank Inc. now owns 20,012 shares of the medical equipment provider’s stock valued at $2,265,000 after buying an additional 163 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Trading Up 1.2%

Shares of ZBH stock opened at $98.18 on Friday. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The firm’s fifty day simple moving average is $100.58 and its 200 day simple moving average is $99.16. The firm has a market capitalization of $19.45 billion, a P/E ratio of 23.89, a price-to-earnings-growth ratio of 2.23 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the previous year, the company earned $2.01 earnings per share. The business’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s payout ratio is currently 23.36%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Evercore ISI decreased their target price on shares of Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a report on Tuesday, July 8th. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Raymond James Financial raised their price target on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Finally, Redburn Partners set a $130.00 price objective on shares of Zimmer Biomet in a research report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $113.16.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.